Newsroom | 44551 results

ZUG, Switzerland--(BUSINESS WIRE)--Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, today announced the signing of a landmark licensing agreement with Argentina-based Tuteur. Under this strategic partnership, Tuteur will obtain exclusive rights to commercialize a biosimilar for autoimmune diseases across Latin America (LATAM), excluding Brazil. Polpharma Biologics will retain full responsibility for the development and ma...

NEW YORK--(BUSINESS WIRE)--Flatiron Health today announced its presence at the American Society of Clinical Oncology (ASCO) Annual Meeting happening from May 29 - June 2, 2026, in Chicago, Illinois. Flatiron's high-quality real-world data and innovative research capabilities are featured across 25+ research acceptances, including 14 Flatiron-authored poster presentations and online publications. Flatiron’s presence at ASCO 2026 closely follows the launch of Flatiron Telescope, a multi-agent ada...

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today updated its fiscal year 2026 financial guidance as a result of recent opportunistic share repurchases. Cencora now expects adjusted diluted earnings per share to be in the range of $17.70 to $17.90, up from the previous range of $17.65 to $17.90. The opportunistic share repurchases completed in May align with the Company’s previously disclosed expectation that it will repurchase $1.0 billion in shares of common stock by the end...

NEW YORK & BURLINGTON, Mass.--(BUSINESS WIRE)--Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly”), today announced that the company will participate at the William Blair 46th Annual Growth Stock Conference. Joseph DeVivo, President, Chief Executive Officer & Chairman and John Doherty, EVP, Chief Financial Officer will participate in a presentation breakout session at 8:40 AM CT on June 4, 2026, and host one-on-one investor meetings throughout the day. A webcast of the presentation will be a...

PARIS & NEW YORK--(BUSINESS WIRE)--Ennov (das „Unternehmen“), ein globaler Anbieter von End-to-End-Softwarelösungen für die Bereiche Regulierung, Qualität und klinische Studien für Life-Science- und Gesundheitsunternehmen, gab heute eine strategische Wachstumsinvestition bekannt, die von Bregal Sagemount („Sagemount“), einer führenden wachstumsorientierten Private-Equity-Gesellschaft, angeführt wird und an der Ardian, eine globale Private-Equity-Gesellschaft, beteiligt ist. Die Investition wird...

PARIGI E NEW YORK--(BUSINESS WIRE)--Ennov (l'"Azienda"), fornitore globale di soluzioni software end-to-end in ambito normativo, di qualità e clinico per le aziende di scienze della vita e sanitarie, ha annunciato oggi un investimento strategico per la crescita guidato da Bregal Sagemount ("Sagemount"), una società di private equity leader orientata alla crescita, con la partecipazione di Ardian, una società di investimento privata di livello globale. L'investimento andrà a sostegno della conti...

PARÍS y NUEVA YORK--(BUSINESS WIRE)--Ennov (la “Empresa”), proveedor global de soluciones de software integrales para cumplimiento regulatorio, calidad y gestión clínica, anunció hoy una inversión de crecimiento estratégico liderada por Bregal Sagemount (“Sagemount”), una firma de capitales privados líder enfocada en el crecimiento, con participación de Ardian, una firma de inversiones privadas global. La inversión respaldará la expansión continua de la Empresa, con especial hincapié en la inno...

PARIJS & NEW YORK--(BUSINESS WIRE)--Ennov (hierna "het Bedrijf"), een wereldwijde leverancier van complete softwareoplossingen op het gebied van regelgeving, kwaliteit en klinische zaken voor bedrijven in de life sciences en gezondheidszorgsector, heeft vandaag een strategische groei-investering aangekondigd. De financiering waaraan ook Ardian, een wereldwijde particuliere investeringsmaatschappij, deelneemt, werd uitgevoerd onder leiding van Bregal Sagemount (“Sagemount”), een toonaangevend, o...

MIAMI--(BUSINESS WIRE)--OpenEvidence, the most widely used medical AI platform among U.S. physicians, today launched Voice Mode, the first native speech-to-speech medical AI interface. With Voice Mode, OpenEvidence becomes the first multimodal medical AI offering a hands-free way for clinicians to ask questions aloud, and hear cited answers read back, on the same peer-reviewed evidence base. The feature is live in the OpenEvidence web and mobile apps and is free for all users. Physicians reach...

EDISON, N.J.--(BUSINESS WIRE)--MTF Biologics, a global nonprofit leader in tissue-based solutions, today announced the appointment of New Horizon Medical Solutions (NHMS) as the exclusive distributor of AmnioBand® Membrane to wound care specialists, podiatrists, and mobile care practitioners across the United States. The agreement combines AmnioBand's peer-reviewed Level 1 clinical evidence base with NHMS's specialized provider network and hands-on field support, creating a distribution model p...